Evaluation of Assumptions Underpinning Pharmacometric Models.

Qing-Xi Ooi, Daniel F B Wright, Geoffrey K Isbister, Stephen B Duffull
Author Information
  1. Qing-Xi Ooi: School of Pharmacy, University of Otago, 63 Hanover Street, Dunedin, 9016, New Zealand. qingxiooi.pmx@gmail.com. ORCID
  2. Daniel F B Wright: School of Pharmacy, University of Otago, 63 Hanover Street, Dunedin, 9016, New Zealand.
  3. Geoffrey K Isbister: School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  4. Stephen B Duffull: School of Pharmacy, University of Otago, 63 Hanover Street, Dunedin, 9016, New Zealand.

Abstract

Assumptions inherent to pharmacometric model development and use are not routinely acknowledged, described, or evaluated. The aim of this work is to present a framework for systematic evaluation of assumptions. To aid identification of assumptions, we categorise assumptions into two types: implicit and explicit assumptions. Implicit assumptions are inherent in a method or model and underpin its derivation and use. Explicit assumptions arise from heuristic principles and are typically defined by the user to enable the application of a method or model. A flowchart was developed for systematic evaluation of assumptions. For each assumption, the impact of assumption violation ('significant', 'insignificant', 'unknown') and the probability of assumption violation ('likely', 'unlikely', 'unknown') will be evaluated based on prior knowledge or the result of an additional bespoke study to arrive at a decision ('go', 'no-go') for both model building and model use. A table of assumptions with standardised headings has been proposed to facilitate the documentation of assumptions and evaluation of results. The utility of the proposed framework was illustrated using four assumptions underpinning a top-down model describing the warfarin-coagulation proteins' relationship. The next step of this work is to apply the framework to a series of other settings to fully assess its practicality and its value in identifying and making inferences from assumptions.

Keywords

References

  1. AAPS J. 2012 Dec;14(4):749-58 [PMID: 22826033]
  2. J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):301-14 [PMID: 25925797]
  3. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 03;2:e51 [PMID: 23836283]
  4. Clin Pharmacol Ther. 2015 Mar;97(3):247-62 [PMID: 25670209]
  5. AAPS J. 2005 Oct 05;7(2):45 [PMID: 16353906]
  6. Nephron. 1976;16(1):31-41 [PMID: 1244564]
  7. Clin Pharmacokinet. 2014 Feb;53(2):111-22 [PMID: 24327237]
  8. Clin Pharmacol Ther. 2012 Jul;92(1):17-20 [PMID: 22713733]
  9. CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):416-417 [PMID: 28653481]
  10. J Pharmacokinet Biopharm. 1998 Apr;26(2):207-46 [PMID: 9795882]
  11. CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2:e63 [PMID: 23945604]
  12. CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122 [PMID: 27069774]
  13. J Pharmacokinet Biopharm. 1995 Dec;23(6):651-72 [PMID: 8733951]
  14. CPT Pharmacometrics Syst Pharmacol. 2017 Mar;6(3):156-167 [PMID: 27863172]
  15. Clin Pharmacokinet. 2017 Dec;56(12):1555-1566 [PMID: 28409488]
  16. Annu Rev Pharmacol Toxicol. 2011;51:45-73 [PMID: 20854171]

MeSH Term

Anticoagulants
Humans
Models, Theoretical
Pharmacokinetics
Pharmacology
Warfarin

Chemicals

Anticoagulants
Warfarin

Word Cloud

Created with Highcharts 10.0.0assumptionsmodelevaluationassumptionuseframeworkAssumptionsinherentevaluatedworksystematicmethodviolation'unknown'proposedpharmacometricdevelopmentroutinelyacknowledgeddescribedaimpresentaididentificationcategorisetwotypes:implicitexplicitImplicitunderpinderivationExplicitariseheuristicprinciplestypicallydefineduserenableapplicationflowchartdevelopedimpact'significant''insignificant'probability'likely''unlikely'willbasedpriorknowledgeresultadditionalbespokestudyarrivedecision'go''no-go'buildingtablestandardisedheadingsfacilitatedocumentationresultsutilityillustratedusingfourunderpinningtop-downdescribingwarfarin-coagulationproteins'relationshipnextstepapplyseriessettingsfullyassesspracticalityvalueidentifyingmakinginferencesEvaluationUnderpinningPharmacometricModelsassessmentmodelspharmacometrics

Similar Articles

Cited By (3)